|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Severin_Schwan
|
|
gptkbp:country
|
gptkb:Switzerland
|
|
gptkbp:foundedBy
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:foundedYear
|
1896
|
|
gptkbp:headquartersLocation
|
Basel
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
F. Hoffmann-La Roche AG
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:logo
|
Roche logo.svg
|
|
gptkbp:marketCap
|
over CHF 200 billion
|
|
gptkbp:memberOf
|
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
CHF 13.5 billion (2023)
|
|
gptkbp:notableEvent
|
Acquisition of Chugai Pharmaceutical (majority stake)
Acquisition of Flatiron Health (2018)
Acquisition of Foundation Medicine (2018)
Acquisition of Genentech (2009)
Acquisition of Ventana Medical Systems (2008)
Development of Actemra for rheumatoid arthritis
Development of Avastin for cancer
Development of COVID-19 diagnostics
Development of Hemlibra for hemophilia A
Development of Herceptin for breast cancer
Development of Ocrevus for multiple sclerosis
Development of Rituxan for lymphoma
Development of Tamiflu for influenza
Development of Tecentriq for cancer immunotherapy
|
|
gptkbp:notableProduct
|
gptkb:Nutropin
gptkb:Saizen
gptkb:Evrysdi
gptkb:Phesgo
gptkb:CellCept
gptkb:Copegus
gptkb:Enspryng
gptkb:Invirase
gptkb:Lariam
gptkb:Mircera
gptkb:NeoRecormon
gptkb:NeutroSpec
gptkb:RoActemra
gptkb:Rocaltrol
gptkb:Roferon-A
gptkb:Rozerem
gptkb:Valcyte
gptkb:Lucentis
gptkb:Venclexta
gptkb:Actemra
gptkb:Alecensa
gptkb:Avastin
gptkb:Bactrim
gptkb:Bonviva
gptkb:Cotellic
gptkb:Erivedge
gptkb:Esbriet
gptkb:Fuzeon
gptkb:Gazyva
gptkb:Hemlibra
gptkb:Herceptin
gptkb:Kadcyla
gptkb:MabThera
gptkb:Madopar
gptkb:Ocrevus
gptkb:Pegasys
gptkb:Perjeta
gptkb:Polivy
gptkb:Rituxan
gptkb:Roaccutane
gptkb:Rocephin
gptkb:Rozlytrek
gptkb:Tamiflu
gptkb:Tarceva
gptkb:Tecentriq
gptkb:Valium
gptkb:Xeloda
gptkb:Xenical
gptkb:Xofluza
gptkb:Zelboraf
gptkb:Dormicum
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:parentCompany
|
gptkb:Roche_Holding_AG
|
|
gptkbp:products
|
pharmaceuticals
biotechnology products
diagnostics
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:revenue
|
CHF 58.7 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:ROG
|
|
gptkbp:subsidiary
|
gptkb:Genentech
gptkb:Foundation_Medicine
gptkb:Chugai_Pharmaceutical
gptkb:Flatiron_Health
gptkb:Ventana_Medical_Systems
|
|
gptkbp:website
|
https://www.roche.com
|
|
gptkbp:bfsParent
|
gptkb:Roche
|
|
gptkbp:bfsLayer
|
6
|